ATE488249T1 - Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung - Google Patents

Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung

Info

Publication number
ATE488249T1
ATE488249T1 AT02748276T AT02748276T ATE488249T1 AT E488249 T1 ATE488249 T1 AT E488249T1 AT 02748276 T AT02748276 T AT 02748276T AT 02748276 T AT02748276 T AT 02748276T AT E488249 T1 ATE488249 T1 AT E488249T1
Authority
AT
Austria
Prior art keywords
hsv
herpes simplex
simplex virus
amino acids
fragment
Prior art date
Application number
AT02748276T
Other languages
English (en)
Inventor
David Koelle
Nancy Hosken
Christine Posavad
Hongbo Chen
Patrick Mcgowan
Original Assignee
Univ Washington
Corixa Corp
Hutchinson Fred Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington, Corixa Corp, Hutchinson Fred Cancer Res filed Critical Univ Washington
Application granted granted Critical
Publication of ATE488249T1 publication Critical patent/ATE488249T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16611Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02748276T 2001-07-31 2002-07-31 Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung ATE488249T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30892301P 2001-07-31 2001-07-31
US30942801P 2001-08-01 2001-08-01
PCT/US2002/024306 WO2003011893A2 (en) 2001-07-31 2002-07-31 Immunologically significant herpes simplex virus antigens and methods for using same

Publications (1)

Publication Number Publication Date
ATE488249T1 true ATE488249T1 (de) 2010-12-15

Family

ID=26976523

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02748276T ATE488249T1 (de) 2001-07-31 2002-07-31 Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung

Country Status (8)

Country Link
US (2) US6814969B2 (de)
EP (2) EP1420821B8 (de)
JP (1) JP4519461B2 (de)
AT (1) ATE488249T1 (de)
AU (1) AU2002317604A1 (de)
CA (1) CA2454750C (de)
DE (1) DE60238330D1 (de)
WO (1) WO2003011893A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2011510T3 (da) 2002-07-18 2011-03-28 Univ Washington Farmaceutiske sammensætninger indeholdende immunologisk aktive Herpes simplex-virus(HSV) proteinfragmenter
AU2004274430A1 (en) 2003-09-12 2005-03-31 Antigenics, Inc. Vaccine for treatment and prevention of herpes simplex virus infection
WO2006113681A2 (en) 2005-04-15 2006-10-26 Human Matrix Sciences, Llc Plant-derived elastin binding protein ligands and methods of using the same
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
EP2521786B1 (de) * 2006-07-20 2015-06-24 Vical Incorporated Zusammensetzungen zur impfung gegen hsv-2
DE112008000888T5 (de) * 2007-04-04 2011-05-19 Hugh Birchwood McTavish Nichtspezifische verzögerte Überempfindlichkeitsreaktion zur Behandlung von Herpes-Simplex-Virusinfektionen
ES2588705T3 (es) 2007-09-27 2016-11-04 Immunovaccine Technologies Inc. Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
CA2723918C (en) 2008-06-05 2018-01-09 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
US8460674B2 (en) * 2009-02-07 2013-06-11 University Of Washington HSV-1 epitopes and methods for using same
EP2413950A4 (de) 2009-04-03 2013-05-01 Univ Washington Antigenes hsv-2-peptid und verwendungsverfahren dafür
AU2010249330B2 (en) 2009-05-22 2015-11-05 Genocea Biosciences Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
US20130224236A1 (en) * 2010-11-03 2013-08-29 University Of Washington Hsv-1 epitopes and methods for using same
AU2011336894B2 (en) 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
IN2014CN02581A (de) 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
AU2012340712B2 (en) 2011-11-23 2017-09-14 Genocea Biosciences, Inc. Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
SI2850431T1 (en) 2012-05-16 2018-08-31 Immune Design Corp. Vaccines for hsv-2
KR102533463B1 (ko) 2015-02-26 2023-05-16 스퀘어렉스 파마슈티컬 코포레이션 단순 포진 바이러스 감염을 치료하기 위한 비특이적 지연형 과민성 반응
WO2017157969A1 (en) * 2016-03-14 2017-09-21 Redbiotec Ag Means and methods for treating hsv
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ, インコーポレイテッド ヘルペスを処置するための方法および組成物
US20200164060A1 (en) * 2017-07-21 2020-05-28 Fred Hutchinson Cancer Research Center Herpes simplex virus vaccine epitopes specifically recognized by tissue resident memory t cells
CN112710849A (zh) * 2020-12-24 2021-04-27 首都医科大学附属北京友谊医院 一种鉴定抗EBV免疫活性的ELISpot试剂盒、制备方法及应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
JP3005292B2 (ja) 1990-08-02 2000-01-31 カイロン コーポレイション 単純ヘルペスウィルスのvp16のワクチン
CA2090295A1 (en) 1992-02-03 1993-08-04 Anthony B. Nesburn Process for the expression of herpes simplex virus type 1 glycoprotein e and methods of use
US5426039A (en) 1993-09-08 1995-06-20 Bio-Rad Laboratories, Inc. Direct molecular cloning of primer extended DNA containing an alkane diol
EP0845043B1 (de) 1995-07-28 2007-06-27 Marie Curie Cancer Care Transportproteine und deren verwendungen
GB9615726D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Anti-viral agent 11
EP0948508A4 (de) 1996-11-04 2001-11-07 Smithkline Beecham Corp Kodierungssequenzen vom herpes-simplex-virus typ 2
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
AU7597998A (en) * 1997-06-02 1998-12-21 Chiron Corporation Herpes simplex virus vp22 vaccines and methods of use
JP2002522451A (ja) * 1998-08-07 2002-07-23 ユニバーシティ オブ ワシントン 免疫学的単純ヘルペスウイルス抗原とその使用法
US6413518B1 (en) * 1999-09-30 2002-07-02 University Of Washington Immunologically significant herpes simplex virus antigens and methods for identifying and using same
US6821519B2 (en) * 2000-06-29 2004-11-23 Corixa Corporation Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
ATE349533T1 (de) * 2000-06-29 2007-01-15 Corixa Corp Zusammensetzung zur diagnose und behandlung von herpes simplex virusinfektionen

Also Published As

Publication number Publication date
EP1420821A4 (de) 2006-08-30
EP1420821B1 (de) 2010-11-17
US20040241182A1 (en) 2004-12-02
US20030190324A1 (en) 2003-10-09
WO2003011893A3 (en) 2003-09-12
EP1420821B8 (de) 2011-02-02
EP2191845A1 (de) 2010-06-02
CA2454750C (en) 2012-09-18
US7037509B2 (en) 2006-05-02
JP4519461B2 (ja) 2010-08-04
AU2002317604A1 (en) 2003-02-17
CA2454750A1 (en) 2003-02-13
JP2004537308A (ja) 2004-12-16
US6814969B2 (en) 2004-11-09
DE60238330D1 (de) 2010-12-30
EP1420821A2 (de) 2004-05-26
WO2003011893A2 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
ATE488249T1 (de) Immunologisch bedeutende herpes-simplex-virus- antigene und verfahren für ihre verwendung
EP2011510A3 (de) Pharmazeutische Zusammensetzungen, die immunologisch aktive Herpes simplex Virus Proteinfragmente enthalten
MX9702714A (es) Produccion de peptidos en plantas como fusiones de proteinas con revestimiento viral.
BG102983A (en) Extramembrane protein 106 polypeptide of moraxella catarrhalis, its gene sequence and application
DE69434413D1 (de) Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
CA2111645A1 (en) Fibrinogen fragment e peptides and antibodies thereto
IL135687A0 (en) A novel human checkpoint kinase, hcds1, compositions and methods
EP0965637A4 (de) Fas ANTIGEN-DERIVATE
PT1417222E (pt) Polipéptidos isolados baseados no epítopo neutralizante da proteína p17 de vih, úteis como vacinas, e anticorpos antip17 neutralizantes que reconhecem especificamente o referido polipéptido neutralizante
DE69233311D1 (de) Weidelgraspollen-allergen
FI930626A0 (fi) Proteinstruktur hos vaexttoxingelonin
PT635025E (pt) Processo para preparar proteinas modificadas
DE69128039D1 (de) Allergene aus roggenspreupollen
AU1444699A (en) Single-chain polypeptides comprising troponin i and troponin
ATE108802T1 (de) Polypeptidhemmer für virale replikation.
DE69928947D1 (de) Moraxella catarrhalis basb034 polypeptide und verwendungen davon
GB2357507A (en) Peptide fragments of cholera toxin B or enterotoxin B as vaccine adjuvants
ATE234358T1 (de) Peptide des pferdearteritisvirus, antikörper und ihre verwendung in einem diagnostischen test
AU6393990A (en) Hiv related peptides
WO2000034294A3 (en) Tumor necrosis factor receptor homologue-1 ('trh1')
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
WO2001070774B1 (en) Human t cell response to mhc-binding motif clusters
NZ606260A (en) Novel polypeptides involved in immune response
MY106940A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.
WO2002000832A3 (fr) Nouveau polypeptide, proteine p80-coiline 8.8, et polynucleotide codant ce polypeptide

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties